JAMA Network JAMA Ophthalmology : Mammalian Target Rapamycin Inhibition for Proliferative Vitreoretinopathy
Aug 7, 2025
In this engaging discussion, Ehsan Rahimy, a leading expert in vitreoretinal diseases, sheds light on the promising role of mTOR inhibitors in preventing proliferative vitreoretinopathy (PVR). He dives into the significance of mTOR as a cellular regulator and its implications for retinal health. Rahimy reviews remarkable data showcasing a 40% reduction in retinal detachment risks through mTOR therapies. Plus, he emphasizes the need for randomized clinical trials to validate excitement in innovative treatments, setting a hopeful tone for future retinal surgeries.
AI Snips
Chapters
Transcript
Episode notes
mTOR's Role in Cell Growth
- mTOR is a key regulator protein kinase that controls cell growth and proliferation.
- This makes it a relevant therapeutic target for diseases like proliferative vitreoretinopathy (PVR).
Common Use of mTOR Inhibitors
- mTOR inhibitors are commonly prescribed, especially for preventing organ transplant rejection.
- These drugs are becoming more popular, even among people seeking longevity benefits in places like Silicon Valley.
Why Focus on mTOR Inhibitors?
- The study focused on mTOR inhibitors due to their potential to modulate immunosuppression and reduce PVR risk.
- mTOR inhibitors have favorable drug characteristics ideal for perioperative use in preventing PVR.